Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

Proof of diagnosis is attained by demonstration of the Philadelphia (Ph) chromosome (22q–)
resulting from the balanced translocation t (9; 22)(q34; q11), and/or the BCR–ABL …

CML is characterized by the presence of the Philadelphia chromosome, which is the product
of a reciprocal translocation between chromosomes 9 and 22 that results in the formation of …

The Philadelphia chromosome translocation (t [9; 22]) results in the molecular juxtaposition
of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR …

Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …

Purpose Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine
kinase protein critical for the pathogenesis of chronic myeloid leukemia. Patients and …

Targeted therapy with the Abl kinase inhibitor imatinib has markedly improved the outlook
for patients with chronic myeloid leukemia (CML). Breakpoint cluster region (Bcr)-Abl …

Imatinib mesylate is a major advance in the therapy of patients with chronic myelogenous
leukemia (CML). Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine …

Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of
chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are …

The deregulated activity of BCR-ABL tyrosine kinase originating from the t (9; 22)
chromosomal translocation has been shown to be necessary and sufficient for the …